Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative LUSZ Therapeutic Study of Antiviral, Antiretroviral, and Immunosuppressive Treatments in Hospitalized COVID-19 Patients With High-Risk Factors, Biomarkers, and Disease Progression

Next Previous
Trial Profile

Comparative LUSZ Therapeutic Study of Antiviral, Antiretroviral, and Immunosuppressive Treatments in Hospitalized COVID-19 Patients With High-Risk Factors, Biomarkers, and Disease Progression

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Remdesivir (Primary) ; Tocilizumab (Primary) ; Alprazolam; Atorvastatin; Ceftriaxone; Doxycycline; Enoxaparin sodium; Ivermectin; Ketoprofen; Methylprednisolone; Omeprazole; Paracetamol; Quetiapine; Vitamin D
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LUSZ_CTS_COVID

Most Recent Events

  • 05 Feb 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2025.
  • 05 Feb 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.
  • 21 Jul 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top